Your browser doesn't support javascript.
loading
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; Ke, Hua; Madison, Russell; Drenth, Anne Paulien; van der Burg, Eline; Schut, Eva; Henneman, Linda; van Miltenburg, Martine H; Proost, Natalie; Zhen, Huiling; Wientjens, Ellen; de Bruijn, Roebi; de Ruiter, Julian R; Boon, Ute; de Korte-Grimmerink, Renske; van Gerwen, Bastiaan; Féliz, Luis; Abou-Alfa, Ghassan K; Ross, Jeffrey S; van de Ven, Marieke; Rottenberg, Sven; Cuppen, Edwin; Chessex, Anne Vaslin; Ali, Siraj M; Burn, Timothy C; Jimenez, Connie R; Ganesan, Shridar; Wessels, Lodewyk F A; Jonkers, Jos.
Afiliación
  • Zingg D; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bhin J; Oncode Institute, Utrecht, The Netherlands.
  • Yemelyanenko J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kas SM; Oncode Institute, Utrecht, The Netherlands.
  • Rolfs F; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lutz C; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lee JK; Oncode Institute, Utrecht, The Netherlands.
  • Klarenbeek S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Silverman IM; Oncode Institute, Utrecht, The Netherlands.
  • Annunziato S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Chan CS; Oncode Institute, Utrecht, The Netherlands.
  • Piersma SR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Eijkman T; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Badoux M; Oncode Institute, Utrecht, The Netherlands.
  • Gogola E; Foundation Medicine, Cambridge, MA, USA.
  • Siteur B; Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sprengers J; Incyte Research Institute, Wilmington, DE, USA.
  • de Klein B; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Goeij-de Haas RR; Oncode Institute, Utrecht, The Netherlands.
  • Riedlinger GM; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Ke H; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.
  • Madison R; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Drenth AP; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Burg E; Oncode Institute, Utrecht, The Netherlands.
  • Schut E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Henneman L; Oncode Institute, Utrecht, The Netherlands.
  • van Miltenburg MH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Proost N; Oncode Institute, Utrecht, The Netherlands.
  • Zhen H; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wientjens E; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Bruijn R; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Ruiter JR; Oncode Institute, Utrecht, The Netherlands.
  • Boon U; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • de Korte-Grimmerink R; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.
  • van Gerwen B; Department of Pathology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Féliz L; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Abou-Alfa GK; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.
  • Ross JS; Foundation Medicine, Cambridge, MA, USA.
  • van de Ven M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rottenberg S; Oncode Institute, Utrecht, The Netherlands.
  • Cuppen E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Chessex AV; Oncode Institute, Utrecht, The Netherlands.
  • Ali SM; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Burn TC; Oncode Institute, Utrecht, The Netherlands.
  • Jimenez CR; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ganesan S; Oncode Institute, Utrecht, The Netherlands.
  • Wessels LFA; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nature ; 609(7929): E13, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36050473
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos